Upregulation of FOXM1 leads to diminished drug sensitivity in myeloma.
Chunyan GuXuefang JingCarol HolmanRamakrishna SompallaeFenghuang ZhanGuido TricotYe YangSiegfried JanzPublished in: BMC cancer (2018)
These findings enhanced our understanding of the emerging FOXM1 genetic network in myeloma and provided preclinical support for the therapeutic targeting of the FOXM1-NEK2 and CDK4/6-Rb-E2F pathways using small-drug CDK and NEK2 inhibitors. Clinical research is warranted to assess whether this approach may overcome drug resistance in FOXM1Hi myeloma and, thereby, improve the outcome of patients in which the transcription factor is expressed at high levels.
Keyphrases
- newly diagnosed
- multiple myeloma
- transcription factor
- end stage renal disease
- cell cycle
- ejection fraction
- peritoneal dialysis
- prognostic factors
- cell proliferation
- genome wide
- poor prognosis
- gene expression
- emergency department
- signaling pathway
- patient reported outcomes
- long non coding rna
- drug delivery
- dna binding
- patient reported